Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY-NC-NDGynecologic Oncology Reports

A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a

  • Tamar A. Gootzen1
  • Alda Birgsdottir2
  • Miranda P. Steenbeek3
  • Michiel Simons4
  • Guro H. Gloersen5
  • Anne Dørum2
  • Joanne A. de Hullu3
5 affiliations
  1. 1Department of Obstetrics and Gynecology, Radboud university Medical Center, Nijmegen, The Netherlands; Corresponding author at: Department of Gynecology and Obstetrics, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
  2. 2Department of Obstetrics and Gynecology, Oslo University Hospital, Oslo, Norway
  3. 3Department of Obstetrics and Gynecology, Radboud university Medical Center, Nijmegen, The Netherlands
  4. 4Department of Pathology, Radboud university Medical Center, Nijmegen, The Netherlands
  5. 5Department of Pathology, Oslo University Hospital, Oslo, Norway
Read full textPDFDOICite

Abstract

Introduction: Risk reducing salpingo-oophorectomy with delayed oophorectomy is an alternative preventive strategy to prevent tubo-ovarian carcinoma. Its oncological safety is currently under investigation within different clinical trials. Case: After a previous salpingectomy, a 37-year-old BRCA1 pathogenic variant carrier developed a carcinoma in the abdominal cavity, which had spread extensively throughout the abdomen. She had chosen the alternative risk-reducing salpingectomy with delayed oophorectomy as tubo-ovarian carcinoma prevention strategy The salpingectomy was performed at age 35, two years prior to the diagnosis of carcinoma. Radiologically, the tumor appeared to originate from the left ovary with lymphadenopathy, hydronephrosis, and peritoneal carcinomatosis. Incomplete debulking surgery was performed with en bloc resection of the uterus, ovaries, rectosigmoid,appendix, and distal part of the left ureter. After extensive analysis with pathology revision, the tumor was classified as a poorly differentiated sarcomatoid urothelial cell carcinoma. Molecular testing showed the tumor had a BRCA1 pathogenic variant. Conclusion: This case illustrates the importance of a structured clinical trial setting for the investigation of cancer prevention strategies as it ensures extensive follow-up and comprehensive pathological (re)assessment to warrant patient safety.

Related

  1. 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. Yersinia Enterocolitica Infection Mimicking Colon Carcinoma With Hepatic Metastases
    Ricarda Lamprecht‐Bailer, Sigrid Sauernheimer, Abbas Agaimy +1
    United European Gastroenterology JournalPeer-reviewedCC BY-NC-ND 4.0Full textGenetics & genomicsPMCEurope PMC
  3. Testing immune priming failure in laryngeal squamous cell carcinoma: direct evidence, unresolved links, and a compartment-resolved framework
    Wei-Zhe Hong, Guan-Jiang Huang, Qi-Ping Luo +1
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  4. Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report
    Qin Xu, Xiaofen Li, Rui Zhu +4
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  5. Chemopreventive potential of Styrax liquidus in a DMBA-induced oral squamous cell carcinoma model
    Dilara Nur Şengün, İnci Rana Karaca, Aysel Uğur +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textPlant biologyCrossref

Cite

BibTeXRIS
BibTeX
@article{gootzen2026urothelial,
  title = {{A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a}},
  author = {Tamar A. Gootzen and Alda Birgsdottir and Miranda P. Steenbeek and Michiel Simons and Guro H. Gloersen and Anne Dørum and Joanne A. de Hullu},
  journal = {Gynecologic Oncology Reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.gore.2026.102232},
  url = {https://doi.org/10.1016/j.gore.2026.102232},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - A urothelial cell carcinoma in the abdominal cavity after salpingectomy for tubo-ovarian carcinoma risk reduction in a
AU  - Tamar A. Gootzen
AU  - Alda Birgsdottir
AU  - Miranda P. Steenbeek
AU  - Michiel Simons
AU  - Guro H. Gloersen
AU  - Anne Dørum
AU  - Joanne A. de Hullu
PY  - 2026
DA  - 2026/10/14
JO  - Gynecologic Oncology Reports
DO  - 10.1016/j.gore.2026.102232
UR  - https://doi.org/10.1016/j.gore.2026.102232
AB  - Introduction: Risk reducing salpingo-oophorectomy with delayed oophorectomy is an alternative preventive strategy to prevent tubo-ovarian carcinoma. Its oncological safety is currently under investigation within different clinical trials. Case: After a previous salpingectomy, a 37-year-old BRCA1 pathogenic variant carrier developed a carcinoma in the abdominal cavity, which had spread extensively throughout the abdomen. She had chosen the alternative risk-reducing salpingectomy with delayed oophorectomy as tubo-ovarian carcinoma prevention strategy The salpingectomy was performed at age 35, two years prior to the diagnosis of carcinoma. Radiologically, the tumor appeared to originate from the left ovary with lymphadenopathy, hydronephrosis, and peritoneal carcinomatosis. Incomplete debulking surgery was performed with en bloc resection of the uterus, ovaries, rectosigmoid,appendix, and distal part of the left ureter. After extensive analysis with pathology revision, the tumor was classified as a poorly differentiated sarcomatoid urothelial cell carcinoma. Molecular testing showed the tumor had a BRCA1 pathogenic variant. Conclusion: This case illustrates the importance of a structured clinical trial setting for the investigation of cancer prevention strategies as it ensures extensive follow-up and comprehensive pathological (re)assessment to warrant patient safety.
SN  - 2352-5789
ER  -